BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
With Cipla Ltd.'s strong domestic franchise, low competitive launch momentum in the U.S. business, and its focus on the respiratory pipeline we expect earnings compound annual growth rate of 14.7% over FY22-24E.
Building further on the commercial front-end acquired through Invagen Pharmaceuticals and Exelan Pharmaceuticals, Cipla has remained among the top 12 most dispensed companies in the U.S.
Cipla is focused on limited competition complex products and launched gAlbuterol and Lanreotide injection.
Albuterol has seen a continued expansion in market share to 17.2%, as at March 2022, of the total market.
We believe a gradual ramp-up in Albuterol and complex launches like gRevlimid, gAbraxane, gAdvair shaping up in H2 FY23 will support medium-term revenue growth.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
